Clinical Trial Simulations: Modeling and Applications

Clinical trial simulation (CTS) is a computational approach that uses mathematical models of drug behavior, disease progression, and patient variability to generate virtual trial data before a real study is conducted. For students, researchers, life-science professionals, and informed general readers, CTS provides a way to test trial designs, compare analysis strategies, and estimate the probability of trial success without exposing patients to experimental treatments. This article explains the methodology behind CTS, its practical applications in dose selection and sample size determination, its role within model-informed drug development, and the software tools commonly used to implement simulations.

What Clinical Trial Simulation Does

Clinical trial simulation applies Monte Carlo methods and other computational techniques to the specific problem of designing and evaluating clinical trials. The core idea is to create virtual patients with realistic physiological and demographic characteristics, administer virtual treatments according to a proposed protocol, and observe simulated outcomes based on mathematical models of drug action and disease progression. By repeating this process thousands of times, researchers can characterize the distribution of possible trial results under different design assumptions.

The pharmaceutical industry and regulatory authorities have recognized modeling and simulation as pivotal to improving the efficiency of drug development. CTS helps researchers learn about drug effectiveness and safety and optimize trial designs at various stages of development. A review of publications from January 2000 through January 2010 discussed developments in CTS methodology, applications, and lessons learned in the development and clinical use of specific drugs. The review anticipated that future CTS experiments would benefit from combining optimal design methods with computationally intensive stochastic simulations, allowing researchers to optimize experimental designs while evaluating the probable real-world performance of a limited number of candidate trial designs and analysis procedures [7].

Clinical trial simulation is not a new statistical technique but rather the application of established methods such as Monte Carlo simulation to the challenge of maximizing information obtained during drug development. When information about a drug is substantial, simulation provides a way to synthesize that knowledge into a coherent package demonstrating that the sponsor understands the pharmacology of the compound. From a financial perspective, simulation offers pharmaceutical companies the possibility of reducing the number of required studies, maximizing the chances of trial success, and potentially shortening development time, all of which reduce drug development costs [8].

Core Components of a Clinical Trial Simulation

A clinical trial simulation requires several interconnected components that together form a virtual representation of the trial and the patients enrolled in it.

Pharmacokinetic and Pharmacodynamic Models

Pharmacokinetic models describe how the drug concentration changes over time in the body, including absorption, distribution, metabolism, and elimination. Pharmacodynamic models describe the relationship between drug concentration and the biological effect. Nonlinear mixed-effect models are commonly used to characterize both processes while accounting for variability between individuals. The simulation of therapeutic models has benefited from fundamental progress in the development of in silico models and from advances in nonlinear mixed-effect pharmacokinetic-pharmacodynamic modeling. Combining these approaches allows simulation of virtual patients who receive virtual treatments or placebo [10].

Disease Progression Models

Disease progression models describe how the underlying condition evolves over time, both naturally and in response to treatment. These models may incorporate biomarkers, clinical endpoints, and patient characteristics that influence the rate of progression. For example, a model-informed clinical trial simulation tool developed for Duchenne muscular dystrophy used disease progression models to simulate trial scenarios and evaluate study designs before actual execution. The tool created a virtual population using a machine learning algorithm to enlarge the available sample size for simulation, and external validation was performed using the placebo arm of a published trial [13].

Patient Population Models

Virtual patients must reflect the demographic, physiological, and genetic diversity of the population that will be enrolled in the real trial. Patient characteristics such as age, weight, organ function, disease severity, and biomarker levels influence drug exposure and response. Simulation models generate virtual patient cohorts by sampling from distributions of these characteristics, often informed by data from previous trials or real-world evidence.

Protocol and Execution Models

The trial protocol specifies the treatment regimen, dosing schedule, visit timing, outcome assessments, and analysis plan. Execution models account for practical realities such as patient dropout, protocol deviations, and missing data. The effect of departures from protocol on clinical trial results can be evaluated using simulation, which is valuable for anticipating the impact of real-world trial conduct on the validity of results [10].

At a Glance: Clinical Trial Simulation Applications

Applications in Trial Design

Clinical trial simulation supports a wide range of design decisions across the drug development lifecycle. The specific applications depend on the stage of development, the availability of prior data, and the questions that need to be answered.

Dose Selection and Optimization

Dose selection is one of the most common applications of CTS. Pharmacokinetic and pharmacodynamic models developed from early-phase data can be used to simulate the outcomes of alternative dosing regimens in later-phase trials. A notable example involved docetaxel in patients with non-small-cell lung cancer. Pharmacokinetic and pharmacodynamic analyses during drug development showed that patients with high baseline alpha1-acid glycoprotein levels had shorter time to progression and time to death. Researchers developed and validated models for time to progression, death, and dropout using phase II data from 151 patients. They then simulated a phase III trial comparing 125 mg/m2 of docetaxel versus 100 mg/m2 in patients with high alpha1-acid glycoprotein levels. The simulation showed that although median survival was slightly longer in the higher-dose group, the difference was significant in only 6 of 100 simulated trials. The low power to detect a difference due to dose intensification was the basis for the decision not to perform such a trial [12].

This example illustrates a critical function of CTS: preventing the initiation of trials that are unlikely to succeed. The simulation exercise yielded valuable insight into how pharmacokinetic- and pharmacodynamic-based simulation can inform go or no-go decisions [12].

Sample Size Determination

Sample size calculations for clinical trials traditionally rely on simple formulas based on expected effect size, variability, and statistical power. CTS provides a more flexible approach that can account for complex design features, patient heterogeneity, dropout patterns, and analysis methods. Simulation-based sample size determination is particularly valuable for adaptive designs, cluster trials, and trials in rare diseases where standard assumptions may not hold.

For rare diseases such as cystic fibrosis, accruing enough patients for clinical trials is challenging. External controls from well-matched historical trials can reduce prospective trial sizes, and this approach has supported regulatory approval of new interventions for other rare diseases. A simulation study compared three statistical methods for incorporating external controls into a hypothetical cystic fibrosis trial: inverse probability weighting, Bayesian modeling with propensity-score-based power priors, and hierarchical Bayesian modeling with commensurate priors. Simulations showed that bias in the treatment effect was less than 4% using any of the methods, with type I error usually less than 5%. The commensurate prior method performed best with real clinical trial data [14].

Adaptive Trial Designs

Adaptive designs allow modifications to a trial based on interim data. Multi-arm multi-stage designs, in which multiple active treatments are compared to a control and accumulated information from interim data is used to add or remove arms, may reduce development costs and shorten the drug development timeline. This adaptive update is a natural complement to Bayesian methodology in which prior clinical belief is sequentially updated using observed probability of success. Simulation is often required for planning such trials to accommodate the complexity of the design and to optimize key design characteristics [9].

Simulation also helps address computational challenges in adaptive designs. Researchers have developed optimized methods for calculating posterior probability and posterior predictive probability of success in Bayesian multi-arm multi-stage designs with binary endpoints, reducing the computational burden and time needed to obtain simulation results [9].

Evaluation of Trial Design Robustness

Conventional clinical trial design methods are not necessarily tailored for the unique characteristics of all therapeutic modalities. For example, late-stage cancer immunotherapy trials often lead to unusual survival curve shapes, such as delayed curve separation or a plateauing curve in the treatment arm. It is critical for trial success to anticipate such effects in advance and adjust the design accordingly. Researchers used in silico cancer immunotherapy trials based on three different mathematical models to assemble virtual patient cohorts undergoing late-stage immunotherapy, chemotherapy, or combination therapies. All three simulation models predicted the distinctive survival curve shapes commonly associated with immunotherapies. By simulating various possible scenarios, the researchers demonstrated how the robustness of trial design choices can be scrutinized and possible pitfalls identified in advance, considering sample size, endpoint, randomization rate, and interim analyses [19].

Cluster and Ring Vaccination Trials

Simulation has proven valuable for designing trials in infectious disease settings where transmission dynamics create complex design challenges. For ring vaccination trials during the 2014-2015 West African Ebola epidemic, researchers developed a stochastic compartmental model to simulate a trial in which rings of primary contacts were vaccinated either immediately or after a delay. The results of simulating the trial were used to calculate the sample size necessary for 80% power, and estimates of effectiveness were reported under various assumptions regarding trial design and implementation. The three key components of sample size calculations, attack rate in controls, estimate of incidence difference between the arms, and intracluster correlation coefficient, were shown to depend on trial design and implementation in ways that could be quantitatively predicted by the model [20].

Another simulation study evaluated the statistical validity and power of randomized controlled and stepped-wedge cluster trial designs in Sierra Leone during the Ebola epidemic. The study found that regional variation in Ebola incidence trends produced inflated false positive rates under standard statistical models for the stepped-wedge design, but not when analyzed by a permutation test. All analyses of randomized controlled trials remained valid. The simulation also estimated that a one-month delay in implementation would reduce the power of the randomized controlled trial by 20% and the stepped-wedge cluster trial by 49% [21].

External Control Integration

The use of external controls from historical trials is an emerging application of CTS, particularly for rare diseases where prospective trial enrollment is difficult. Simulation studies help evaluate the statistical properties of different methods for integrating external controls and guide the choice of analysis approach. The simulation study in cystic fibrosis demonstrated that inverse probability weighting was sensitive to similarity in the prevalence of covariates between historical and prospective trial populations, while hierarchical Bayesian modeling with commensurate priors performed best with real clinical trial data [14].

Model-Informed Drug Development Context

Clinical trial simulation operates within the broader framework of model-informed drug development (MIDD), an approach increasingly adopted by industry and regulatory agencies to improve dose optimization, trial design, and decision-making throughout the drug development pipeline. The pharmaceutical industry faces major challenges in drug discovery and development, with overall success rates of only 10-20%, often due to reductionist approaches that fail to account for complex biological networks. MIDD and quantitative systems pharmacology (QSP) have emerged as responses to this challenge [15].

The widespread adoption of MIDD and QSP methodologies is hindered by a shortage of trained scientists, as traditional biomedical engineering curricula often lack the advanced mathematical and computational modeling preparation required by industry. Educational programs have begun integrating MIDD principles into graduate curricula and launching dedicated master's programs in QSP to provide structured, industry-aligned training [15].

Within the MIDD framework, clinical trial simulation serves as the bridge between mechanistic understanding of drug action and the practical decisions required to design informative clinical trials. Dermal physiologically based pharmacokinetic modeling, for example, integrates skin absorption, formulation characteristics, and systemic kinetics to assist in dermal drug product development and regulatory decision-making within the MIDD framework while reducing expensive clinical trials [16].

Practical Workflow for Conducting a Clinical Trial Simulation

The following workflow outlines the steps required to conduct a clinical trial simulation, from model development to scenario evaluation. This process is iterative, with each step informing refinements to the models and design assumptions.

Step 1: Define the Question and Success Criteria

Before any simulation work begins, the specific question to be answered must be clearly articulated. Examples include: What dose should be taken into phase III? What sample size is needed to detect a clinically meaningful effect? Should an interim analysis be included, and if so, what stopping rules should apply? Success criteria should be defined in terms of the probability of achieving a statistically significant and clinically meaningful result under specified assumptions.

Step 2: Develop or Select the Models

The simulation requires models for pharmacokinetics, pharmacodynamics, disease progression, and patient dropout. These models may be developed from existing trial data, adapted from published literature, or built de novo based on mechanistic understanding. Model development should follow established practices for model building, validation, and documentation. The Assay Guidance Manual from the National Center for Advancing Translational Sciences provides relevant context for understanding the relationship between assay measurements and model inputs [3].

Step 3: Generate the Virtual Patient Population

Virtual patients are generated by sampling from distributions of demographic, physiological, and genetic characteristics. The distributions should reflect the target patient population for the proposed trial. Machine learning algorithms can be used to enlarge available sample sizes for virtual population generation, as demonstrated in the Duchenne muscular dystrophy simulation tool [13].

Step 4: Simulate the Trial Protocol

The trial protocol is implemented in the simulation environment, including treatment assignments, dosing schedules, visit timing, outcome assessments, and analysis procedures. The simulation should account for realistic trial conduct issues such as dropout, protocol deviations, and missing data.

Step 5: Run the Simulation and Collect Results

The simulation is run repeatedly, typically thousands of times, to generate a distribution of possible trial outcomes. Each run represents one possible realization of the trial under the specified assumptions. The number of runs must be sufficient to obtain stable estimates of key operating characteristics such as power, type I error, and bias.

Step 6: Evaluate Design Scenarios

Alternative design scenarios are simulated and compared. This may involve varying the sample size, dosing regimen, endpoint definition, analysis method, or adaptive design parameters. The goal is to identify the design that best balances the probability of success, cost, duration, and participant burden.

Step 7: Validate and Document

Simulation outputs should be validated against available data where possible. For example, the Duchenne muscular dystrophy tool was externally validated using the placebo arm of a recently published trial [13]. Documentation should include the model equations, parameter estimates, assumptions, and simulation code to ensure reproducibility and support regulatory submissions.

Software Tools for Clinical Trial Simulation

Several software platforms support clinical trial simulation, ranging from general-purpose statistical packages to specialized trial simulation tools.

R and R Shiny

R is a widely used open-source statistical programming language that provides the flexibility to implement custom simulation models. The R Shiny framework allows developers to create interactive web applications with graphical user interfaces for navigating various simulation scenarios. A tutorial for creating model-based clinical trial simulation tools using R Shiny described the structural framework, essential controllers, and visualization techniques for analysis, along with key code examples such as criteria selection and power calculation. The tutorial was developed using an example of a model-based clinical trial simulation tool for Duchenne muscular dystrophy [13].

Specialized Pharmacometric Software

Commercial and academic software packages for nonlinear mixed-effect modeling, such as NONMEM, Monolix, and Phoenix NLME, provide the modeling foundation for many clinical trial simulations. These tools support the development of pharmacokinetic and pharmacodynamic models that serve as the basis for simulation.

Quantitative Systems Pharmacology Platforms

QSP platforms integrate mechanistic models of biological pathways with pharmacokinetic and pharmacodynamic models. These platforms are increasingly used for model-informed drug development, particularly for complex diseases where reductionist approaches have failed to account for complex biological networks [15]. Spatial quantitative systems pharmacology models have been developed to simulate tumor progression at the organ scale while capturing spatial heterogeneity, as demonstrated in a computational model for hepatocellular carcinoma [11].

Web-Based Simulation Tools

Web-based implementations of trial simulation models have been developed to facilitate use by biomedical researchers, doctors, and trialists. For example, readily usable web-based implementations of three trial simulation models for cancer immunotherapy were provided to support the evaluation of trial design choices [19].

Records and Measurements in Clinical Trial Simulation

Proper documentation of simulation activities is essential for reproducibility, regulatory submission, and organizational learning. The following records should be maintained for each simulation project.

Model Documentation

Model documentation should include the mathematical equations, parameter estimates with uncertainty intervals, model development history, and validation results. This documentation supports the credibility of the simulation and allows others to understand the assumptions underlying the results.

Simulation Protocol

A simulation protocol should specify the objectives, models, virtual population characteristics, trial design parameters, number of simulation runs, and analysis methods. The protocol should be written before the simulation is conducted to prevent bias in the selection of scenarios and interpretation of results.

Simulation Results

Results should include the distribution of key outcomes across simulation runs, operating characteristics of the design (power, type I error, bias), and sensitivity analyses exploring the impact of alternative assumptions. Results should be presented in a format that supports decision-making, including tables and figures that communicate the probability of success under different scenarios.

Version Control

Simulation code and models should be maintained under version control to track changes over time. This is particularly important when models are updated based on new data or when simulation results inform regulatory submissions.

Common Failure Patterns in Clinical Trial Simulation

Understanding common failure patterns helps researchers avoid pitfalls and interpret simulation results appropriately.

Overfitting to Historical Data

Models developed from limited historical data may not generalize to the target trial population. This is particularly concerning when the historical data come from different patient populations, disease stages, or treatment settings than the proposed trial. The docetaxel example illustrates the importance of validating models against independent data before using them for simulation [12].

Inadequate Exploration of Assumptions

Simulation results depend heavily on the assumptions embedded in the models. Failure to explore the sensitivity of results to alternative assumptions can lead to overconfident predictions. Sensitivity analyses should systematically vary key parameters and assess the impact on trial operating characteristics.

Ignoring Trial Execution Realities

Simulations that assume perfect protocol adherence, no dropout, and complete data will overestimate the probability of trial success. Realistic simulations must account for the effect of departures from protocol on clinical trial results [10].

Computational Burden and Time Constraints

Simulation studies can be computationally intensive, particularly for complex adaptive designs or mechanistic models. The computational burden and time needed to obtain results are key limiting factors in simulation studies. Optimizing methods for calculating posterior probabilities and predictive probabilities can reduce this burden [9].

Misinterpretation of Simulation Results

Simulation results provide estimates of the probability of trial success under specified assumptions. They do not guarantee actual trial outcomes. Decision-makers must understand the distinction between simulated probabilities and real-world results and should consider the full range of simulated outcomes instead of focusing on point estimates.

Limitations of Clinical Trial Simulation

Clinical trial simulation has inherent limitations that must be acknowledged when interpreting results.

Model Validity

The validity of simulation results depends entirely on the validity of the underlying models. Models are simplifications of reality and may not capture all relevant biological, clinical, and operational factors. External validation against independent data is essential but not always possible, particularly for novel mechanisms of action or diseases with limited prior data.

Data Requirements

Developing robust models requires substantial data from previous trials, observational studies, or mechanistic experiments. For early-stage compounds with limited data, models may be highly uncertain, and simulation results should be interpreted with appropriate caution.

Complexity and Expertise

Conducting rigorous clinical trial simulations requires expertise in pharmacokinetics, pharmacodynamics, statistics, and computational methods. The shortage of trained scientists in modeling and simulation is a recognized barrier to the widespread adoption of MIDD methodologies [15].

Regulatory Acceptance

While regulatory authorities have recognized the value of modeling and simulation, the acceptance of simulation results in regulatory submissions varies by context and jurisdiction. Researchers should consult relevant regulatory guidance and engage with regulators early when simulation results are intended to support regulatory decisions.

Safety and Regulatory Context

Clinical trial simulation has important safety implications, both in terms of the trials it helps design and the regulatory framework within which it operates.

Participant Safety

By improving trial design and reducing the likelihood of failed trials, CTS contributes to participant safety. Well-designed trials are more likely to yield informative results, reducing the number of participants exposed to ineffective or harmful treatments. Simulation can also be used to evaluate the safety implications of alternative dosing regimens before they are tested in humans.

Regulatory Guidance

Regulatory authorities have recognized the value of modeling and simulation in drug development. The U.S. Food and Drug Administration has issued guidance on bioanalytical method validation that supports the reliable measurement of drug concentrations in biological matrices, which is foundational for pharmacokinetic modeling [4]. The World Health Organization has published guidance on laboratory quality management and biosafety that is relevant to the laboratory measurements underlying model development [1][2].

Model-Informed Drug Development

Regulatory agencies, including the FDA, are increasingly adopting model-informed drug development approaches to improve dose optimization, trial design, and decision-making throughout the drug development pipeline [15]. Clinical trial simulation is a key component of this framework, providing the quantitative basis for design decisions that are submitted to regulators.

Professional Escalation Criteria

Researchers and teams conducting clinical trial simulations should escalate concerns to appropriate decision-makers or regulatory authorities under specific circumstances.

Escalate When Model Validation Fails

If external validation of simulation models reveals substantial discrepancies between predicted and observed outcomes, the simulation results should not be used for design decisions until the models are revised and revalidated. This escalation should occur before any go or no-go decisions are made based on simulation results.

Escalate When Simulation Results Conflict with Clinical Judgment

If simulation results suggest a design decision that conflicts with established clinical knowledge or prior experience, the discrepancy should be investigated before proceeding. This may indicate a flaw in the models, an error in the simulation implementation, or a genuine insight that warrants further exploration.

Escalate When Regulatory Submission Is Planned

When simulation results are intended to support regulatory submissions, the modeling and simulation plan should be discussed with regulatory authorities early in the process. This is particularly important for novel methodologies, adaptive designs, or external control approaches where regulatory expectations may not be well established.

Escalate When Data Quality Is Inadequate

Simulation results are only as reliable as the data used to develop and validate the models. If data quality issues are identified, such as problems with bioanalytical method validation [4] or laboratory quality management [1], the simulation should be paused until the data issues are resolved.

Frequently Asked Questions

What is the difference between clinical trial simulation and a virtual clinical trial?

Clinical trial simulation and virtual clinical trial are terms that are often used interchangeably, but they can refer to different concepts. Clinical trial simulation refers to the computational process of generating virtual trial data using mathematical models of drug action, disease progression, and patient variability. A virtual clinical trial may refer to a simulation of an entire trial or to a trial conducted using decentralized methods where participants are enrolled and followed remotely. In the context of model-informed drug development, virtual clinical trials are typically simulations that generate synthetic patient data to evaluate trial designs and predict outcomes [10][13].

How many simulation runs are needed for reliable results?

The number of simulation runs depends on the complexity of the trial design, the variability in the models, and the precision required for the estimates. Simple designs with low variability may require only a few thousand runs to obtain stable estimates of power and type I error. Complex adaptive designs or models with high variability may require hundreds of thousands of runs. Researchers should assess the stability of simulation results by running the simulation multiple times with different random seeds and comparing the results. The computational burden and time needed to obtain results are key limiting factors that must be balanced against the need for precision [9].

Can clinical trial simulation replace traditional sample size calculations?

Clinical trial simulation complements instead of replaces traditional sample size calculations. Traditional formulas provide quick estimates based on simplifying assumptions about effect size, variability, and analysis methods. Simulation provides a more flexible framework that can accommodate complex design features, patient heterogeneity, dropout patterns, and alternative analysis approaches. For simple designs, traditional calculations may be sufficient. For complex designs, simulation is often necessary to obtain reliable estimates of operating characteristics. Simulation can also be used to evaluate the robustness of sample size calculations to violations of the assumptions underlying traditional formulas [9][20].

What data are needed to develop a clinical trial simulation model?

The data requirements depend on the complexity of the models and the stage of drug development. Pharmacokinetic models typically require concentration-time data from phase I studies. Pharmacodynamic models require measures of biological effect or clinical outcomes. Disease progression models may require natural history data from observational studies or placebo arms of previous trials. Patient dropout models require data on withdrawal rates and reasons from previous trials. When data are limited, models can be informed by literature values and mechanistic understanding, but the uncertainty in the simulation results will be correspondingly higher [12][13].

How are virtual patients generated in clinical trial simulation?

Virtual patients are generated by sampling from distributions of demographic, physiological, and genetic characteristics that reflect the target trial population. These distributions are typically informed by data from previous trials, electronic health records, or epidemiological studies. Each virtual patient is assigned values for characteristics such as age, weight, organ function, disease severity, and biomarker levels. These characteristics influence drug exposure through the pharmacokinetic model and clinical outcomes through the pharmacodynamic and disease progression models. Machine learning algorithms can be used to enlarge available sample sizes for virtual population generation when data are limited [13].

What is the role of clinical trial simulation in regulatory submissions?

Clinical trial simulation can support regulatory submissions by providing evidence that the proposed trial design is adequate to address the study objectives, that the chosen doses are likely to be effective and safe, and that the analysis plan has appropriate statistical properties. Regulatory authorities have recognized the value of modeling and simulation in drug development, and model-informed drug development approaches are increasingly adopted by industry and regulatory agencies [15]. However, the acceptance of simulation results in regulatory submissions varies by context and jurisdiction. Researchers should engage with regulators early when simulation results are intended to support regulatory decisions.

How does clinical trial simulation handle patient dropout and missing data?

Patient dropout and missing data are handled through execution models that simulate the probability and timing of dropout based on patient characteristics, treatment assignment, and observed outcomes. The simulation can evaluate the impact of different dropout rates and patterns on the validity and power of the trial. The effect of departures from protocol on clinical trial results can be evaluated using simulation, which is valuable for anticipating the impact of real-world trial conduct [10]. Simulation can also be used to compare alternative methods for handling missing data, such as multiple imputation or mixed-effects models.

What skills are needed to conduct clinical trial simulation?

Conducting clinical trial simulation requires expertise in pharmacokinetics, pharmacodynamics, statistics, and computational methods. Specific skills include nonlinear mixed-effect modeling, Monte Carlo simulation, programming in languages such as R, and knowledge of clinical trial design and analysis. The shortage of trained scientists in modeling and simulation is a recognized barrier to the widespread adoption of model-informed drug development methodologies. Educational programs have begun integrating these principles into graduate curricula to address this gap [15].

Related Articles

• Multiplex Real-Time RT-PCR for Differential Diagnosis of Canine Infectious Respiratory Disease Complex (CIRDC): Panel Design, Validation, and Clinical Utility
• How to Design Primers for qPCR: Rules and Tools
• PCR Primer Design: Rules, Tools, and Validation
• How to Design Primers for Site-Directed Mutagenesis: Rules, Tools, and Validation
• DNA Ladder Selection Guide: Choosing the Right Size Marker for Your Gel

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• PubMed. National Library of Medicine.
• Clinical trial simulation: a review.. Clinical pharmacology and therapeutics, 2010.
• Clinical trial simulation in drug development.. Pharmaceutical research, 2000.
• Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.. Journal of biopharmaceutical statistics, 2019.
• Clinical trial simulation in drug development.. Therapie, 2004.
• Integration of Clinical Trial Spatial Multiomics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery.. Cancer research, 2024.
• Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.. Clinical pharmacology and therapeutics, 2000.
• A model-informed clinical trial simulation tool with a graphical user interface for Duchenne muscular dystrophy.. CPT: pharmacometrics & systems pharmacology, 2025.
• Statistical approaches for the integration of external controls in a cystic fibrosis clinical trial: a simulation and an application.. American journal of epidemiology, 2024.
• Model-Informed Drug Development: Addressing the Critical Need for Training in the Promising New Field.. 2026.
• Dermal PBPK modeling in the era of model-informed drug development: Strategies, innovations, and regulatory impact.. 2026.
• TRIAL DESIGN SIMULATION : A Critical Tool in Adaptive. 2009.
• Evaluation of biases present in the cohort multiple randomised controlled trial design: a simulation study. BMC Medical Research Methodology, 2017.
• In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome. Nature Communications, 2023.
• Using simulation to aid trial design: Ring-vaccination trials. bioRxiv, 2016.
• The statistical power and validity of Ebola vaccine trials in Sierra Leone: A simulation study of trial design and analysis. Lancet. Infectious Diseases (Print), 2015.
• Design and analysis of clinical trial simulations. Developments in Statistical Evaluation of Clinical Trials, 2014.
• Nurse-Driven Simulations to Prepare and Educate for a Clinical Trial. Clinical Simulation in Nursing, 2019.
• Model-based integration for clinical trial simulation and design: A phase II case study for naratriptan. Simulation for Designing Clinical Trials A Pharmacokinetic Pharmacodynamic Modeling Perspective, 2002.
• Modeling and simulation in clinical trials. Simulation Series, 2016.

This article is educational and does not replace institutional policy, professional advice, or applicable safety and regulatory requirements.